870.2500 -2.45 (-0.28%)
NSE Jul 10, 2025 15:52 PM
Volume: 387.7K
 

870.25
-0.28%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading above its 150 day SMA of 713.7
More from Strides Pharma Science Ltd.
Recommended